Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1

作者: Joseph Schoepfer , Paul William Manley , Robert Martin Grotzfeld , Pascal Furet , Xavier Francois Andre Pelle

DOI:

关键词:

摘要: The present invention relates to compounds of formula (I): in which Y, R, R 2, 3 and 4 are defined the Summary Invention; capable inhibiting activity BCR-ABL1 mutants thereof. further provides a process for preparation invention, pharmaceutical preparations comprising such methods using treatment cancers.

参考文章(92)
D. Fabbro, G. Fendrich, V. Guez, T. Meyer, P. Furet, J. Mestan, J. D. Griffin, P. W. Manley, S. W. Cowan-Jacob, Targeted Therapy with Imatinib: An Exception or a Rule? Inhibitors of Protein Kinases and Protein Phosphates. ,vol. 167, pp. 361- 389 ,(2005) , 10.1007/3-540-26670-4_13
R. R. C. New, Liposomes : a practical approach IRL Press : Oxford University Press. ,(1990)
Yun He, Guobao Zhang, Barun Okram, Pamela A. Albaugh, Yi Liu, Xia Wang, Zuosheng Liu, Xiaodong Wang, Pingda Ren, Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment ,(2008)
Valeria Caiolfa, Gabriele Fachin, Antonino Suarato, Francesco Angelucci, Fabrizio Orzi, Moreno Zamai, Polymeric derivatives of camptothecins ,(1998)
Andreas Fredenhagen, Giorgio Caravatti, Staurosporine derivatives substituted at methylamino nitrogen ,(1991)
Marcel Robert Kling, Christopher John Burns, Nicotinamide-based kinase inhibitors ,(2003)
Jean Jacques, André Collet, Samuel H. Wilen, Enantiomers, Racemates, and Resolutions ,(1981)